European Psychiatry
January 1, 2025
Marianne Destoop, Pavel Mohr, Florence Butlen‐ducuing et al.
7 citations
The European Psychiatric Association (EPA) acknowledges the therapeutic potential of psychedelic substances for mental disorders, such as psilocybin for depression, which are nearing regulatory approval in the US and Europe. This policy paper highlights both the benefits and challenges of psychedelic treatments, emphasizing the importance of psychosocial components and ethical, professional aspects for real-world implementation. Four recommendations are formulated to guide further research and clinical integration, aiming for safe, ethical, and equitable access for all patients who may benefit.
Psychiatria polska
June 30, 2024
Piotr Gałecki, Katarzyna Maria Bliźniewska-Kowalska, Wiesław Jerzy Cubała et al.
5 citations
A Polish expert panel developed national treatment standards for intravenous racemic ketamine in depressive disorders, addressing the one-third of depressed patients who do not respond to standard antidepressants. The guidelines summarize research on ketamine's efficacy and safety for unipolar and bipolar depression, leveraging its action as an NMDA receptor antagonist to modulate the overactive glutamatergic system implicated in depression. The recommendations cover indications, contraindications, precautions, and treatment protocols, aiming to expand therapeutic options for practicing psychiatrists.
Alcoholism and Drug Addiction
August 31, 2022
Katarzyna Karaś, Katarzyna Groblińska, Krzysztof Szczygieł et al.
Psychoactive substances, particularly psychedelics like psilocybin and LSD, offer immediate therapeutic effects for depression and anxiety in terminal illness without the adverse effects of standard antidepressants, such as extrapyramidal syndrome or sexual disorders. Ketamine has proven effectiveness for depressive disorders and has been introduced as a new treatment. This review covers mechanisms, uses, and side effects of classic psychedelics, empathogens, cannabinoids, stimulants, and dissociants, noting that some substances have strong evidence for treating mental disorders including PTSD, substance dependence, ADHD, and Tourette's Syndrome.